<DOC>
	<DOCNO>NCT00325351</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment new drug call ZK-Epothilone ( ZK-Epo ) give carboplatin patient recurrent ovarian cancer , previously good response cisplatin carboplatin , safe help decrease stop tumor growth .</brief_summary>
	<brief_title>ZK-Epo Given With Carboplatin Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This study previously register Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc. sponsor trial .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Must evidence ovarian cancer measurable compute tomography ( CT ) scan CA125 blood level No radiation therapy last 4 week No chemotherapy last 24 week No immunotherapy last 4 week Good response previous treatment carboplatin cisplatin ovarian cancer get bad least 6 month Additional criterion determine screen visit Exclusion Criteria : Having one treatment regimen carboplatin cisplatin Prior treatment epothilones ( e.g . ixabepilone ) Use investigational drug last 4 week Previous radiation whole pelvis Symptomatic brain tumor require radiation brain Active infection Pregnant breast feed Additional criterion determine screen visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Ovarian neoplasm , epithelium</keyword>
</DOC>